博客

免疫球蛋白

考虑使用IVIG治疗PANS/PANDAS?以下5件事你应该知道

Little girl receiving IVIG treatment for PANS/PANDAS

If your child is living with PANS/PANDAS, 免疫球蛋白 can be an effective treatment option, especially in severe cases. 

询问 IVIG 家庭输液

(877) 778-0318

For some families, however, the IVIG治疗费用 can be an issue. For others, the lack of access to IVIG can make things difficult as well. 

In this article, you will get the latest information about when to consider IVIG for PANS/PANDAS, how much the treatment costs are, the potential risks, and more. 

A Quick Overview of PANS/PANDAS

PANS

PANS is an acronym for Pediatric Acute-onset Neuropsychiatric Syndrome. 

It is a medical condition that causes children to develop abrupt, possibly overnight, obsessive-compulsive disorder (OCD) or eating restrictions. In addition, they may also exhibit symptoms of depression, irritability, anxiety, sleep disturbances, and problems with schoolwork.

The exact cause is unknown. However, it is believed that infections, metabolic disturbances, or immune reactions may trigger PANS.  

PANDAS

PANDAS is an acronym for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. 

It is a medical condition characterized by sudden OCD or tics (involuntary movements) following a recent streptococcal infection, such as strep throat or scarlet fever. PANDAS patients may also display symptoms of irritability, emotional changes, anxiety, and problems with schoolwork.

PANS/PANDAS is a rare condition. According to a new 2023 study, the estimated annual incidence of this condition is 1 in nearly 12,000 children between 3 and 12 years annually [1]. 

1. When to Consider IVIG for PANS/PANDAS?

The PANDAS Physicians Network strongly recommends considering IVIG for PANS/PANDAS if the symptoms cause significant problems to your child’s daily functioning. 

You should work with your child’s provider and specialists to decide if IVIG is appropriate for your child. 

Not all children need IVIG. Experts say that only 10% to 15% of children require IVIG. About 1 in 20 children will require long-term IVIG treatment [2].

2. How Effective Is IVIG for PANS/PANDAS? A Look at the Scientific Evidence

IVIG can be an effective treatment option for children who don’t benefit from antibiotics, behavioral therapy (talk therapy), steroids, and NSAIDs (nonsteroidal anti-inflammatory drugs). 

In many cases, a single course of IVIG may reduce symptoms and even reverse PANDAS [3].

Several studies suggest that IVIG for PANS/PANDAS can dramatically improve symptoms. 

For example, in a 2021 study, researchers administered IVIG (Octagam 5%) infusions every 3 weeks for a total of 6 infusions over a period of 18 weeks to 21 participants between 4 and 16 years [4].

At the end of the study, they found that all the participants experienced over 50% improvement in their symptoms for at least 8 weeks following treatment and a subset of those patients experienced improvement up to 46 weeks following treatment. 

Swedish researchers observed similar results in a 2022 trial. In this trial, 10 children (median age 10 years) received IVIG 2 g/kg monthly for 3 months. 9 children had at least 30% improvement in their symptoms [5].

Most members of the PANS Research Consortium (PRC) prefer IVIG to oral or intravenous steroids for moderate-to-severe PANS [6].

In conclusion, research for the use of IVIG for PANS/PANDAS is ongoing. Available evidence shows promising results, and IVIG is worth a try. 

与专家交谈

关于共付额援助
咨询 IVIG 专家

3. What Are the Potential Risks of Using IVIG for PANS/PANDAS?

Headache, nausea, vomiting, and fever are the common side effects. In rare cases, IVIG may cause:

  • Potentially life-threatening allergic reactions
  • 贫血
  • Aseptic meningitis-like illness

4. Is IVIG for PANS/PANDAS FDA-Approved?

No treatments, including IVIG, are FDA-approved for PANS/PANDAS. 

However, doctors may prescribe specific medications based on their clinical experience and available data. Such practice is known as off-label use. 

5. What Is the Cost of IVIG for PANS/PANDAS?

Cost varies considerably depending on dose and weight. It can be as high as $25,000 [7]. Because the FDA has yet to approve IVIG for PANS/PANDAS, Medicaid doesn’t cover IVIG [8].

Contact your insurance provider for questions related to coverage for IVIG for PANS/PANDAS. IVIG treatment may require prior authorization from your insurance company prior to administration.  

参考:

  1. Wald, Ellen R et al. “Estimate of the incidence of PANDAS and PANS in 3 primary care populations.” Frontiers in pediatrics vol. 11 1170379. 21 Sep. 2023, doi:10.3389/fped.2023.1170379
  2. “Oregon Health Authority Quality and Health Outcomes Committee AGENDA.” Oregon.gov, www.oregon.gov/oha/HPA/DSI/QHOCMeetingDocuments/2022-06-QHOC%20Materials%20Packet.pdf.
  3. “MEMORANDUM.” www.kslegislature.org, Nov. 2021, www.kslegislature.org/li_2022/b2021_22/committees/ctte_s_fin_inst_ins_1/documents/testimony/20220310_24.pdf.
  4. Melamed, Isaac et al. “Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.” Journal of child and adolescent psychopharmacology vol. 31,2 (2021): 118-128. doi:10.1089/cap.2020.0100
  5. Hajjari, Parisa et al. “Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children.” BMC psychiatry vol. 22,1 535. 6 Aug. 2022, doi:10.1186/s12888-022-04181-x
  6. Melamed, Isaac et al. “Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.” Journal of child and adolescent psychopharmacology vol. 31,2 (2021): 118-128. doi:10.1089/cap.2020.0100
  7. Kaitlyn Budion State House News Service, Fall River Herald News. “High Cost of Treating PANDAS Disorder Leaves Families in Bind.” The Herald News, 15 July 2019, www.heraldnews.com/story/news/2019/07/15/high-cost-treating-pandas-disorder/4691123007.
  8. “Health Insurance – Pediatric Autoimmune Neuropsychiatric Disorders – Modification of Coverage Requirements.” https://mgaleg.maryland.gov/mgawebsite, mgaleg.maryland.gov/2022RS/fnotes/bil_0000/hb0820.pdf.
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
Portrait of Samantha K., a healthcare professional or patient representative.
医学审核人 Samantha Kaeberlein 博士,药学博士

Samantha Kaeberlein 博士,药学博士,在俄亥俄州坎顿出生长大。她于 2020 年获得东北俄亥俄医科大学 (NEOMED) 的药学学位。她工作中最有意义的部分是提供医疗指导,帮助患者做出明智、全面的医疗保健决策。她的专业领域是老年医学和长期护理。闲暇时,她喜欢户外活动、阅读,以及寻找美国最好的咖啡。

联系我们

使用下方符合 HIPAA 标准的表格申请续药。如果您对药物或用药方法有任何疑问,请访问“联系我们”页面或致电 (877) 778-0318.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知

zh_CNChinese